TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$17.38
-0.25 (-1.42%)
âŧ
5d:
-0.97%
30d:
+1.34%
90d:
+4.64%
WAIT
LOW Confidence
Analysis Updated: Aug 17, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TAK is fairly priced but lacks strong directional signals. At 1.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TAK is fairly priced but lacks strong directional signals. At 1.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
24.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $17.38, which is considered slightly high relative to its 30-day fair value range of $16.68 to $17.47. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.2). At these levels, the market is pricing in 1.0% annual earnings growth.
Technical Outlook: Technically, TAK is in a downtrend. The price is approaching resistance at $17.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.95 (+26.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TAK is in a downtrend. The price is approaching resistance at $17.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.95 (+26.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$16.68 -
$17.47
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
46.2%
All Signals
- BEARISH: Weak technical setup (27/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.3% below Wall St target ($21.95)
- BULLISH: Expecting earnings turnaround to 1.0% growth with 10.2% revenue growth
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.68 -
$17.47
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$16.30
Resistance Level
$17.66
Current Trend
Downtrend
Technical data as of
Aug 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.18
Wall Street Target
$21.95
(+26.3%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
-9.8%
Profit Margin
-3.5%
Valuation Premium vs History
+1.0% premium
PE vs Historical
0.2 vs 0.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$17.55
(+1%)
2-Year Target
$17.73
(+2%)
3-Year Target
$17.91
(+3%)
3-Yr Target (if PE normalizes)
(PE: 0â0)
$19.57
(+13%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 93.0%)
$6446.55
(+36992%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$58.66
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$49.86
(+187%)
Share & Embed Analysis
Last updated: August 18, 2026 5:36 AM ET
Data refreshes hourly during market hours. Next update: 6:36 AM
Data refreshes hourly during market hours. Next update: 6:36 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 64 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$653 | 53 HOLD |
|
ALKS
Alkermes Plc |
BUY
15 analysts |
$56 | 68 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 42 HOLD |
